Biofrontera Q2 2023 preliminary revenue $5.7M-$5.9M, up 26%-31% YoY; reaffirms FY growth 25%

Biofrontera Inc.

2023-Q2 EPS reported -$12.73 revenue$14,580,000

Q2 2023 preliminary revenue range $5.7M-$5.9M, a 26%-31% increase over Q2 2022.
H1 2023 revenue estimated at $14.4M-$14.6M, reflecting 1%-3% growth YoY.
Full-year 2023 revenue growth reaffirmed at least 25% over 2022.
Management cites increasing adoption of photodynamic therapy and larger contract wins.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Biofrontera Inc. reported the six months ended June 30, 2023 results: revenue in the range of approximately $14.4 million to $14.6 million. Guidance reaffirmed.

Period: the six months ended June 30, 2023
Revenue: in the range of approximately $14.4 million to $14.6 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the range of approximately $14.4 million to $14.6 million, representing growth of approximately 1% to 3% compared with the first half of 2022. “We are proud of the hard work of our commercial teams, which resulted in

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Biofrontera Inc. reported the three months ended June 30, 2023 results: revenue in the range of approximately $5.7 million to $5.9 million. Guidance reaffirmed.

Period: the three months ended June 30, 2023
Revenue: in the range of approximately $5.7 million to $5.9 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

announced preliminary unaudited revenues for the three months ended June 30, 2023. Revenues for the second quarter of 2023 are anticipated to be in the range of approximately $5.7 million to $5.9 million, an increase of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the

View on SEC.gov

Browse all earnings releases →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-024400

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.